Physician profile
Subha Elango
NPI 1841465994
$2,468.42
in general payments reported to CMS, 2019-2025
27 companies · $67.50 in 2025
The $67.50 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $495 · 2021: $1,386 · 2022: $48.36 · 2023: $52.08 · 2024: $419 · 2025: $67.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $538.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $321.10 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $313.78 | 2020-2021 | |
| Glaxosmithkline, LLC. | $207.91 | 2021-2025 | Shingrix, Arexvy, Bexsero |
| Abbvie INC. | $190.41 | 2021 | |
| Exact Sciences Corporation | $159.72 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $151.14 | 2024 | Korlym |
| Amarin Pharma, INC. | $144.11 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $100.56 | 2020-2021 | |
| Novo Nordisk INC | $91.28 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $83.71 | 2021 | |
| Astellas Pharma US INC | $79.99 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.32 | 2021 | |
| Amgen INC. | $65.28 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $63.40 | 2020-2021 | |
| Pfizer INC. | $62.37 | 2022-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $52.04 | 2020-2024 | Gardasil 9, M-M-R II, Gardasil |
| Eisai INC. | $47.55 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $46.26 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.99 | 2020-2021 | |
| Abbott Laboratories | $38.28 | 2022-2024 | Freestyle Libre 3 |
| Boston Scientific Corporation | $26.29 | 2024 | |
| Grifols USA, LLC | $24.13 | 2024 | Prolastin-C Liquid |
| Allergan, INC. | $20.18 | 2020 | |
| Mylan Specialty L.P. | $18.73 | 2021 | |
| Esperion Therapeutics, INC. | $17.63 | 2021 | |
| Ibsa Pharma INC. | $14.59 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subha Elango listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.